Cover Image
市場調查報告書

全球乳癌疫苗的臨床試驗分析

Global Breast Cancer Vaccine Clinical Trial Insight

出版商 KuicK Research 商品編碼 317505
出版日期 內容資訊 英文 134 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
全球乳癌疫苗的臨床試驗分析 Global Breast Cancer Vaccine Clinical Trial Insight
出版日期: 2014年10月29日 內容資訊: 英文 134 Pages
簡介

癌症疫苗,對沒有有效治療方法的複數癌症來說,成為可能實行的治療選項。癌症疫苗市場,分成治療疫苗和預防疫苗。這數年,肽的癌症疫苗,表示出乳癌治療的臨床實驗上的可能性。今後3∼5年,最初的乳癌疫苗可能在市場登場。

本報告提供全球乳癌疫苗市場相關調查分析、概要、臨床實驗平台(各企業、各相、各國)、疫苗的機制、定製(個體化)疫苗、開發平台臨床分析、主要疫苗等相關的系統性資訊。

第1章 全球乳癌疫苗市場概要

  • 目前方案
  • 全球乳癌疫苗開發平台概要

第2章 全球乳癌疫苗市場趨勢

  • 理想的市場參數
    • 研究開發的增加
    • 潛在需求
    • 高齡化、相關要素
    • 意識的高漲
  • 市場課題

第3章 乳癌疫苗的機制

第4章 定製(個體化)癌症疫苗:進展、可能性

第5章 全球乳癌疫苗市場未來發展預測

第6章 全球乳癌疫苗開發平台:各相、各企業、各國

  • 前臨床
  • 第一階段
  • 第一/二階段
  • 第二階段
  • 第三階段

第7章 開發中斷或中止的乳癌疫苗開發平台:各相、各企業、各國

  • 沒有開發報告
  • 中止
  • 中斷

第8章 競爭情形

  • AlphaVax
  • Galena Biopharma
  • Generex Biotechnology
  • GlaxoSmithKline
  • Immune Design
  • Imugene
  • Immunovative Therapies
  • Immunovaccine
  • TapImmune
  • ViroMed

圖表

目錄

Report Highlight:

  • Global Breast Cancer Vaccine Market Overview
  • Global Breast Cancer Vaccine Clinical Pipeline by Company, Phase & Country
  • Mechanism of Breast Cancer Vaccine & Personalized Cancer Vaccines
  • Detailed Clinical Insight on Breast Cancer Vaccine Pipeline: 35 Vaccines
  • Majority in PHASE-I Clinical Trial: 12 Vaccines
  • Highest Clinical Phase is PHASE-III: 2 Vaccines (NeuVax & OBI-822)

Cancer vaccines have emerged viable option for treating multiple cancers which in the present day scenario do not have effective treatments. Therapeutic cancer vaccines and Prophylactic cancer vaccines are the two broad segments into which the cancer vaccines market is categorized. Therapeutic or Treatment vaccines are targeted at treating an existing cancer by strengthening the body's natural defenses against the cancer while the Prophylactic or Preventive vaccines are used to prevent cancer from developing in healthy people. With the approval of the prostate cancer vaccine, Provenge by Dendreon, the field of cancer vaccines has received an unprecedented boost. Consequently, many companies are expected to enter this highly profitable emerging field of preventing, treating, and potentially curing the cancer.

In last few years, the peptide cancer vaccines have been demonstrating potential in clinical trials for the treatment of breast cancer. The high versatility and easy modification capabilities have made them widely acceptable among oncologists. They are sometimes developed to target over expressed receptors specific to the breast cancer cells. These vaccines stimulate a cancer patients' immune system to identify and eliminate breast cancer cells. Clinical trials have also shown the efficacy of peptide vaccines in shrinking breast cancer. This has encouraged the oncologists to develop better breast cancer vaccine for patients.

The development and deciphering of underlying principle of breast cancer vaccine will improve significantly driven by technological advancement occurred in recent years. Innovative products developed in this way will decrease the development time and will also help in cost arbitrage. Without cost effectiveness it would be difficult for pharmaceutical companies to compete and occupy substantial share in breast cancer market. However, it is expected that the cost of these vaccines would be high at the time of introduction which will subsequently decrease due to availability of other vaccines in same category.

It is most likely that the first breast cancer vaccines would be introduced in market in the next 3-5 years period. Clinical trials would be able to come with thoroughly checked version of products under investigation which would be able to provide higher levels of medical care to breast cancer patients. Most of the innovative products are at the final stages of clinical trials which are supposed to clear the targeted end points.

Table of Contents

1. Global Breast Cancer Vaccine Market Overview

  • 1.1 Current Scenario
  • 1.2 Global Breast Cancer Vaccine Pipeline Overview

2. Global Breast Cancer Vaccine Market Dynamics

  • 2.1 Favorable Market Parameters
    • 2.1.1 Increasing Research & Development
    • 2.1.2 Potential Demand
    • 2.1.3 Ageing Population & Related Factors
    • 2.1.4 Increasing Awareness
  • 2.2 Market Challenges

3. Mechanism of Breast Cancer Vaccine

4. Personalized Cancer Vaccines: Progress & Possibilities

5. Global Breast Cancer Vaccine Market Future Prospects

6. Global Breast Cancer Vaccines Pipeline by Phase, Company & Country

  • 6.1 Preclinical
  • 6.2 Phase-I
  • 6.3 Phase-I/II
  • 6.4 Phase-II
  • 6.5 Phase-III

7. Suspended & Discontinued Breast Cancer Vaccines Pipeline by Phase, Company & Country

  • 7.1 No Development Reported
  • 7.2 Discontinued
  • 7.3 Suspended

8. Competitive Landscape

  • 8.1 AlphaVax
  • 8.2 Galena Biopharma
  • 8.3 Generex Biotechnology
  • 8.4 GlaxoSmithKline
  • 8.5 Immune Design
  • 8.6 Imugene
  • 8.7 Immunovative Therapies
  • 8.8 Immunovaccine
  • 8.9 TapImmune
  • 8.10 ViroMed
  • Figure 1-1: Global Breast Cancer Vaccine Clinical Pipeline by Phase (%)
  • Figure 1-2: Global Breast Cancer Vaccine Clinical Pipeline by Phase (Number)
  • Figure 1-3: No Development Reported in Breast Cancer Vaccine Clinical Pipeline by Phase (%)
  • Figure 1-4: No Development Reported in Breast Cancer Vaccine Clinical Pipeline by Phase (Number)
  • Figure 1-5: Discontinued Breast Cancer Vaccine Clinical Pipeline by Phase (%)
  • Figure 1-6: Discontinued Breast Cancer Vaccine Clinical Pipeline by Phase (Number)
  • Figure 1-7: Suspended Breast Cancer Vaccine Clinical Pipeline by Phase (%)
  • Figure 1-8: Suspended Breast Cancer Vaccine Clinical Pipeline by Phase (%)
  • Figure 2-1: Favorable Parameters for Breast Cancer Vaccine Development
  • Figure 2-2: Challenges for Breast Cancer Vaccine Market
  • Figure 3-1: Schematic Representation of NeuVax Breast Cancer Vaccine Development
  • Figure 3-2: Effects of Cryoablation Procedure
  • Figure 3-3: Steps Involved in the Development of AlloStim
  • Figure 4-1: Overview of Personalized Cancer Vaccines Development
  • Figure 4-2: Methodology for the Development of Personalized Cancer Vaccine
  • Figure 4-3: Schematic Representation of Development of Skin Implant for Cancer Vaccine
  • Figure 8-1: AlphaVax Clinical Pipeline Overview
  • Figure 8-2: Galena Biopharma Clinical Pipeline Overview
  • Figure 8-3: Generex Biotechnology Clinical Pipeline Overview
  • Figure 8-4: Immune Design Clinical Pipeline Overview
  • Figure 8-5: Imugene Clinical Pipeline Overview
  • Figure 8-6: Immunovaccine Clinical Pipeline Overview
  • Figure 8-7: TapImmune Clinical Pipeline Overview
  • Figure 8-8: ViroMed Clinical Pipeline Overview
  • Table 5-1: Different Types of Biomarkers for Personalized Cancer Vaccine Development
Back to Top